Truist Securities Downgrades Corcept Therapeutics (CORT) to Hold

Truist Securities analyst Gregory Fraser downgraded Corcept Therapeutics (NASDAQ: CORT) from Buy to Hold with a price target of $30.00.

For an analyst ratings summary and ratings history on Corcept Therapeutics click here. For more ratings news on Corcept Therapeutics click here.

Shares of Corcept Therapeutics closed at $28.66 yesterday.

You May Also Be Interested In

• Canaccord Downgrades York Space Systems (YSS) to Hold, 'Supply chain and contract timing uncertainty'
• Cantor Fitzgerald Downgrades EyePoint Inc. (EYPT) to Neutral
• Johnson Rice Downgrades Expand Energy (EXE) to Accumulate